Nuvation Bio Expands Safusidenib Rights; Wedbush Bullish: Wedbush reiterated a bullish view on NUVB after Nuvation expanded safusidenib rights on Apr 12, 2026; shares jumped ~18% on Apr 13, 2026, market cap near… 👈 Read full analysis #NuvationBio #Safusidenib #Wedbush #StockMarket #Pharmaceuticals
Nuvation Bio Expands Safusidenib Rights; Wedbush Bullish
Wedbush reiterated a bullish view on NUVB after Nuvation expanded safusidenib rights on Apr 12, 2026; shares jumped ~18% on Apr 13, 2026, market cap near $1.8bn (Apr 13, 2026).
dlvr.it
April 13, 2026 at 1:31 AM
Nuvation Bio Expands Safusidenib Rights; Wedbush Bullish: Wedbush reiterated a bullish view on NUVB after Nuvation expanded safusidenib rights on Apr 12, 2026; shares jumped ~18% on Apr 13, 2026, market cap near… 👈 Read full analysis #NuvationBio #Safusidenib #Wedbush #StockMarket #Pharmaceuticals
NuVation Bio Files DEF 14A on April 10, 2026: NuVation Bio filed Form DEF 14A on April 10, 2026 (Investing.com at 15:30:34 GMT), initiating its 2026 proxy season and shareholder vote timetable. 👈 Read full analysis #NuVationBio #DEF14A #ProxySeason #ShareholderVote #Investing
NuVation Bio Files DEF 14A on April 10, 2026
NuVation Bio filed Form DEF 14A on April 10, 2026 (Investing.com at 15:30:34 GMT), initiating its 2026 proxy season and shareholder vote timetable.
dlvr.it
April 10, 2026 at 4:23 PM
NuVation Bio Files DEF 14A on April 10, 2026: NuVation Bio filed Form DEF 14A on April 10, 2026 (Investing.com at 15:30:34 GMT), initiating its 2026 proxy season and shareholder vote timetable. 👈 Read full analysis #NuVationBio #DEF14A #ProxySeason #ShareholderVote #Investing
Nuvation Bio Files Form 144 on April 6, 2026: Nuvation Bio filed a Form 144 on Apr 6, 2026; Rule 144 requires filing when sales exceed 5,000 shares or $50,000 and allows a 90-day sale window (Investing.com, SEC). 👈 Read full analysis #NuvationBio #Form144 #Investing #StockMarket #SEC
Nuvation Bio Files Form 144 on April 6, 2026
Nuvation Bio filed a Form 144 on Apr 6, 2026; Rule 144 requires filing when sales exceed 5,000 shares or $50,000 and allows a 90-day sale window (Investing.com, SEC).
dlvr.it
April 6, 2026 at 11:17 PM
Nuvation Bio Files Form 144 on April 6, 2026: Nuvation Bio filed a Form 144 on Apr 6, 2026; Rule 144 requires filing when sales exceed 5,000 shares or $50,000 and allows a 90-day sale window (Investing.com, SEC). 👈 Read full analysis #NuvationBio #Form144 #Investing #StockMarket #SEC
#NuvationBio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor #Ibtrozi as a treatment for ROS1-positive non-small cell lung cancer (#NSCLC).
pharmaphorum.com/news/fda-cle...
pharmaphorum.com/news/fda-cle...
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
pharmaphorum.com
June 12, 2025 at 1:55 PM
#NuvationBio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor #Ibtrozi as a treatment for ROS1-positive non-small cell lung cancer (#NSCLC).
pharmaphorum.com/news/fda-cle...
pharmaphorum.com/news/fda-cle...
